These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36065128)

  • 1. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.
    Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R
    BJPsych Open; 2022 Sep; 8(5):e163. PubMed ID: 36065128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 4. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
    Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL
    J Affect Disord; 2023 Aug; 334():100-112. PubMed ID: 37146908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.
    Mertens LJ; Wall MB; Roseman L; Demetriou L; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2020 Feb; 34(2):167-180. PubMed ID: 31941394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
    Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; Lennard-Jones MR; Licht RW; Marwood L; Mistry S; Páleníček T; Redjep O; Repantis D; Schoevers RA; Septimus B; Simmons HJ; Soares JC; Somers M; Stansfield SC; Stuart JR; Tadley HH; Thiara NK; Tsai J; Wahba M; Williams S; Winzer RI; Young AH; Young MB; Zisook S; Malievskaia E
    J Affect Disord; 2023 Apr; 327():120-127. PubMed ID: 36740140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic science in post-COVID-19 psychiatry.
    Kelly JR; Crockett MT; Alexander L; Haran M; Baker A; Burke L; Brennan C; O'Keane V
    Ir J Psychol Med; 2021 Jun; 38(2):93-98. PubMed ID: 32811575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
    Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS
    CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
    Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME
    Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of psilocybin for treatment-resistant depression].
    Johannesdottir A; Sigurdsson E
    Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psilocybin compared with escitalopram for depression].
    Strous JFM
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Role of Serotonergic Hallucinogens in Depression Treatment.
    Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
    Lyons A
    Innov Clin Neurosci; 2022; 19(7-9):44-47. PubMed ID: 36204170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.